Graves Ophthalmopathy Clinical Trial
Official title:
Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy
Grave's ophthalmopathy is the most common cause of orbital disease in adults. The clinical
presentation may vary between sub clinic symptoms to severe ones. The eyelid retraction is
one of the most important signs of Grave's ophthalmopathy and can lead to cosmetic and
functional problems.
The eyelid retraction can be found in the inflammatory stage and in the chronic disease,
when it is stable. It can be described when the upper lid is contouring the superior limbus
or positioned above that. This condition can lead to dry eye symptoms, exposure keratitis
and cosmetic issues. The treatment can may be surgical or medical.
The medical treatment are usually based on controlling thyroid function and in the use of
steroids, both are not specific for the lid retraction, but for the inflammation that is
common in the disease.
In the longstanding disease, surgery is the most efficient treatment. There are several
described techniques, they are based on the concept of weakening the muscles that act on lid
elevation (levator and Muller Muscle).
Basically the techniques can be divided in two groups: the first with an anterior approach
(with skin scar in the lid sulcus) and the second using a posterior approach (through the
conjunctiva).
In the literature there is no consensus in deciding the best technique, regarding cosmetic
results, incidence of complications, hypo or hypercorrection.
In this trial we propose to compare two distinct techniques that are already in clinical
use. The blepharotomy uses a cutaneous approach and the other a conjunctival approach.
The patients will be divided in two randomized groups and surgical expected outcomes,
cosmetics outcomes and complications occurrence will be compared.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | February 2015 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 21 Years and older |
Eligibility |
Inclusion Criteria: - > 21 years old - controlled thyroid function - absence of strabismus - absence of other ocular pathology, such as high myopia - understanding the protocol and according the terms Exclusion Criteria: - pregnancy - history of previous upper lid surgery - myasthenia gravis |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Brazil | Hospital das Clinicas - FMUSP | São Paulo | SP |
Lead Sponsor | Collaborator |
---|---|
University of Sao Paulo |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | clinical measure of the Margin Reflex distance | Assessment of the surgical correction effectiveness by measuring the eyelid lengthening | 6 months | Yes |
Secondary | evaluation of ocular surface with OSDI (Ocular Surface Disease Index) questionnaire, clinical measures with Schirmmer test green lissamine and tear film breakup Time. | OSDI (Ocular Surface Disease Index) is a questionnaire of dry eye symptoms Schirmmer test - measures tear production green lissamine test - evaluate ocular surface damage Tear film Break Up Time - evaluate tear's quality | 6 months | Yes |
Secondary | From the patients digital photographs,computed assisted measurements of eyelid shape and contour will be performed. | with a specific software (contour) the contour and shape of the operated eyelids will be measured. Comparison will be made with previous photographs and of normal subjects. |
6 months | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05532072 -
Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.
|
Early Phase 1 | |
Completed |
NCT01727973 -
Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT06112340 -
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
|
Phase 2/Phase 3 | |
Recruiting |
NCT05678374 -
Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease
|
||
Recruiting |
NCT03708627 -
Bimatoprost as a Treatment for Graves' Orbitopathy
|
Early Phase 1 | |
Not yet recruiting |
NCT06413043 -
Study on Efficacy of Add on Selenium in Mild-to-moderate Graves Ophthalmopathy
|
N/A | |
Withdrawn |
NCT01379196 -
Use of Azithromycin as Immunomodulatory Therapy in Grave&Apos;s Orbitopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT06275373 -
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
|
||
Recruiting |
NCT06226545 -
A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
|
Phase 2 | |
Recruiting |
NCT05126147 -
Hydroxychloroquine in Mild Graves' Orbitopathy
|
Phase 4 | |
Recruiting |
NCT03066076 -
Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy
|
Phase 3 | |
Active, not recruiting |
NCT03122847 -
Glucocorticoids and Bone in Graves' Ophthalmopathy
|
||
Terminated |
NCT01893450 -
Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment
|
N/A | |
Completed |
NCT00348413 -
Thyroid Treatment Trial
|
N/A | |
Completed |
NCT03498417 -
Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy
|
||
Not yet recruiting |
NCT04598815 -
Sirolimus for Graves' Orbitopathy (GO)
|
Phase 2 | |
Terminated |
NCT01114503 -
A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease
|
Phase 2 | |
Completed |
NCT05775185 -
Therapeutic Efficacy of Orbital Radiotherapy in Patients With Graves' Orbitopathy
|
||
Completed |
NCT05793359 -
Comparison of the Effectiveness of Two Glucocorticoid Regimens for Treatment of Graves' Orbitopathy
|
||
Recruiting |
NCT02203682 -
Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy
|
Phase 2 |